Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), has announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% from the market price on August 15 [1][2] Group 1 - The placement shares represent approximately 2.25% of the total issued shares as of the announcement date and about 2.20% of the total issued shares after the placement [1] - The placement is being conducted by CICC as the placement agent, with the sole subscriber being TruMed Health Innovation Fund LP, a Cayman Islands registered exempt limited partnership focused on healthcare stocks [1] - The expected total proceeds from the placement are approximately HKD 100 million, with a net amount of about HKD 99 million after expenses [2] Group 2 - Approximately 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowing for R&D expenses, thereby improving the company's financial position [2] - About 30% of the net proceeds will be allocated for the development of new product pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]
荃信生物-B(02509.HK)拟折价10.95%向TruMed基金配售500万股 总筹1亿港元